Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Show more

11 Hurley Street, Cambridge, MA, 02141, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

184.5M

52 Wk Range

$0.91 - $4.54

Previous Close

$1.89

Open

$1.91

Volume

3,602,136

Day Range

$1.91 - $2.29

Enterprise Value

192.4M

Cash

165.6M

Avg Qtr Burn

-30.84M

Insider Ownership

0.52%

Institutional Own.

54.45%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EDIT-401 Details Hyperlipidemia, Atherosclerotic cardiovascular disease (ASCVD)	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Genetic disorder, Beta thalessemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Sickle cell disease, Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EDIT-101 Details Rare diseases, Eye disease , Rare genetic disease, Hepatitis C	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.